Scholarlink

Introduction <p>Alopecia areata (AA) is an inflammatory hair loss disorder, which negatively impacts health-related quality of life (HRQoL). This study investigates treatment patterns and HRQoL by AA disease severity.</p> Methods <p>Data were drawn from the Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and patients in the USA from November 2023 to June 2024. Dermatologists reported patient demographics, clinical characteristics, treatment patterns, and mental health. Patients completed AA Symptom Impact Scale, Skindex-16 AA, and Work Productivity and Activity Impact questionnaires. Data were stratified by AA-Investigator Global Assessment (IGA) scores and physician-assessed disease severity.</p> Results <p>Overall, 65 physicians reported on 501 patients, of whom 81 self-reported data. In total, 211 patients had severe/very severe AA-IGA-scored AA, of whom 66% received oral Janus kinase and 31% received non-topical corticosteroids. Among 501 patients, 43% had concomitant conditions. Anxiety (74%) and depression (61%) were most prevalent in severe/very severe AA-IGA-scored AA. Patients with severe/very severe AA reported notably high mean (standard deviation) scores on the global AA Symptom Impact Scale (AA-IGA, 3.1 [2.5]; physician-assessed, 3.0 [2.4]), Skindex-16 Emotion subscale (AA-IGA, 59.5 [29.8]; physician-assessed, 59.8 [27.5]) and overall work impairment (AA-IGA, 16.2% [21.4]; physician-assessed, 17.5% [20.2]).</p> Conclusions <p>This study showed that AA severity may correlate with HRQoL, highlighting the need for validated severity measures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Arash Mostaghimi,
  • Ahmed M. Soliman,
  • Sven G. Richter,
  • Jenny Austin,
  • Alexa Russnak

摘要

Introduction

Alopecia areata (AA) is an inflammatory hair loss disorder, which negatively impacts health-related quality of life (HRQoL). This study investigates treatment patterns and HRQoL by AA disease severity.

Methods

Data were drawn from the Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and patients in the USA from November 2023 to June 2024. Dermatologists reported patient demographics, clinical characteristics, treatment patterns, and mental health. Patients completed AA Symptom Impact Scale, Skindex-16 AA, and Work Productivity and Activity Impact questionnaires. Data were stratified by AA-Investigator Global Assessment (IGA) scores and physician-assessed disease severity.

Results

Overall, 65 physicians reported on 501 patients, of whom 81 self-reported data. In total, 211 patients had severe/very severe AA-IGA-scored AA, of whom 66% received oral Janus kinase and 31% received non-topical corticosteroids. Among 501 patients, 43% had concomitant conditions. Anxiety (74%) and depression (61%) were most prevalent in severe/very severe AA-IGA-scored AA. Patients with severe/very severe AA reported notably high mean (standard deviation) scores on the global AA Symptom Impact Scale (AA-IGA, 3.1 [2.5]; physician-assessed, 3.0 [2.4]), Skindex-16 Emotion subscale (AA-IGA, 59.5 [29.8]; physician-assessed, 59.8 [27.5]) and overall work impairment (AA-IGA, 16.2% [21.4]; physician-assessed, 17.5% [20.2]).

Conclusions

This study showed that AA severity may correlate with HRQoL, highlighting the need for validated severity measures.